Angelini Pharma’s international Public Affairs initiative “Headway2020 : A new roadmap in Mental Health” goes public ahead of the 27th World Mental Health Day at the European Parliament.

With healthcare policies, medical guidelines and not surprisingly prescriptions increasingly under scrutiny from both Health Authorities and budget holders, the goals for healthcare professional communications are rapidly changing.

The acquired products include BoxaGrippal® (ibuprofen/pseudoephedrine) a Pharmacy-Only OTC brand.

Angelini supports Italian Red Cross providing medicines to people in Venezuela whose lives have been shattered by violence and instability.

On May 17 Angelini Pharma signed a deal with EUSA Pharma to be the exclusive distributor of Fotivda (Tivozanib), a product indicated for the first line treatment of adult patients with advanced renal cell carcinoma (RCC).

The Board of Directors of Angelini Holding S.p.A., is pleased to announce that Pierluigi Antonelli has been appointed as the new CEO of Angelini Pharma, effective March 4th, 2019.